CeriBell Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 46 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 26.86.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CeriBell Inc's Score
Industry at a Glance
Industry Ranking
46 / 204
Overall Ranking
125 / 4565
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
CeriBell Inc Highlights
StrengthsRisks
CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining highly portable and rapidly deployable hardware with artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared (510(k)) for indicating suspected seizure activity and utilized in intensive care units and emergency rooms across the United States. Clarity, its machine learning algorithm, continuously interprets a patient’s EEG waveforms and displays actionable insights regarding seizure activity on the recorder. Its EEG portal is a cloud-based portal that enables real-time remote access to a patient’s EEG data.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 96.93% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 89.06M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 89.06M.
Fairly Valued
The company’s latest PE is -12.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 31.90M shares, decreasing 4.88% quarter-over-quarter.
CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining highly portable and rapidly deployable hardware with artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared (510(k)) for indicating suspected seizure activity and utilized in intensive care units and emergency rooms across the United States. Clarity, its machine learning algorithm, continuously interprets a patient’s EEG waveforms and displays actionable insights regarding seizure activity on the recorder. Its EEG portal is a cloud-based portal that enables real-time remote access to a patient’s EEG data.